What is the recommended ceftriaxone dose (intravenous) for an adult with Klebsiella bacteremia?

Recommended Ceftriaxone Dose for Klebsiella Bacteremia in Adults

For adult patients with Klebsiella bacteremia, administer ceftriaxone 2 grams intravenously once daily, which is the FDA-approved standard dose for serious infections and provides adequate therapeutic exposure for susceptible Enterobacterales bloodstream infections. 1

FDA-Approved Dosing for Adults

• The FDA label specifies that the usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection, with a maximum total daily dose of 4 grams. 1
• For serious infections including bacteremia, the 2-gram once-daily dose represents the upper end of standard dosing and is appropriate for bloodstream infections caused by susceptible organisms. 1
• No dosage adjustment is necessary for patients with renal or hepatic impairment. 1

Evidence Supporting 2-Gram Dosing for Enterobacterales Bacteremia

Pharmacokinetic Data

• A 2025 pharmacokinetic study in septic patients demonstrated that 1 gram once daily is unlikely to achieve therapeutic unbound trough concentrations (≥0.5 mg/L) in >90% of patients with creatinine clearance ≥60 mL/min presenting with sepsis. 2
• The same study showed that 2 grams once daily achieves therapeutic exposure for target pathogens in patients with creatinine clearance ≤140 mL/min. 2

Clinical Outcomes Data

• A 2022 retrospective cohort study comparing 1 gram versus 2 grams daily for Enterobacterales bacteremia found no statistically significant difference in 90-day clinical failure rates (16.7% vs 9.6%, P=0.260), though there was a numerical trend toward increased infection relapse in the 1-gram group (11.1% vs 1.9%, P=0.078). 3
• A 2025 retrospective analysis showed clinical failure rates of 21.7% with 1 gram versus 35.4% with 2 grams (P=0.08), though this difference was not statistically significant. 4
• A 1989 study using ceftriaxone 1-4 grams daily for severe bacteremic infections (including 9 episodes of Klebsiella pneumoniae) achieved complete recovery in 84.8% of patients, with mean treatment duration of 10.8 days. 5

Practical Dosing Algorithm

Step 1: Confirm susceptibility

• Verify that the Klebsiella isolate is susceptible to ceftriaxone (MIC ≤1 mg/L per CLSI breakpoints). 6
• If susceptibility testing is pending, ceftriaxone is appropriate empiric therapy for community-acquired Klebsiella bacteremia in patients without risk factors for ESBL-producing organisms. 6

Step 2: Standard dosing

• Administer ceftriaxone 2 grams IV once daily for most adult patients with Klebsiella bacteremia. 1, 2
• Infuse over 30 minutes in adults. 1

Step 3: Consider higher dosing for specific scenarios

• For patients with hypoalbuminemia (a risk factor for clinical failure), strongly consider the 2-gram dose rather than 1 gram. 3
• For patients with augmented renal clearance (CrCl >140 mL/min), consider increasing to 2 grams twice daily (total 4 grams daily) to maintain therapeutic concentrations. 2
• For CNS infections (meningitis), use 2 grams IV every 12 hours (total 4 grams daily). 1

Step 4: Duration of therapy

• Continue therapy for at least 2 days after signs and symptoms of infection have disappeared. 1
• Usual duration is 4-14 days; complicated infections may require longer therapy. 1

Alternative Consideration: Cefazolin

• A 2021 retrospective study from Singapore demonstrated that cefazolin may be a ceftriaxone-sparing alternative for antibiotic-susceptible Klebsiella pneumoniae bacteremia, with comparable 28-day mortality (10.5% vs 7.1%, P=0.403). 6
• This option addresses concerns about excessive ceftriaxone use creating selection pressure for ESBL-producing organisms. 6
• However, cefazolin remains a second-line option pending prospective randomized controlled trial data. 6

Critical Pitfalls to Avoid

• Do not use 1 gram once daily as the default dose for bacteremia, as pharmacokinetic data suggest inadequate exposure in many patients. 2
• Do not underdose patients with hypoalbuminemia, who have a 4-fold increased risk of clinical failure (OR 4.03,95% CI 1.12-14.50). 3
• Do not use ceftriaxone for carbapenem-resistant Klebsiella pneumoniae (CRKP), which requires carbapenem-based therapy or newer agents like ceftazidime-avibactam. 7, 8
• Ensure source control is achieved (e.g., drainage of abscesses, removal of infected catheters), as antibiotics alone may be insufficient. 5